Metabolomics analysis of metabolic effects of nicotinamide phosphoribosyltransferase (NAMPT) inhibition on human cancer cells

PLoS ONE

Volumn 9, Issue 12, 2014, Pages

  Tolstikov, Vladimir ^a,b   Nikolayev, Alexander ^a   Dong, Sucai ^a   Zhao, Genshi ^a   Kuo, Ming Shang ^a  

^a ELI LILLY AND COMPANY   (United States)

^b Berg LLC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; ARGININE; ASPARTIC ACID; CARNITINE; CYSTEINE; DAPORINAD; FATTY ACID; GLYCINE; HISTIDINE; METHIONINE; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; NICOTINIC ACID; PALMITIC ACID; PROLINE; SERINE; STEARIC ACID; AMINO ACID; CREATINE; PURINE; PURINE DERIVATIVE; PYRIMIDINE; PYRIMIDINE DERIVATIVE;

AMINO ACID METABOLISM; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CARBOHYDRATE METABOLISM; COLORECTAL CANCER; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; ENZYME INHIBITION; GLYCOLYSIS; HUMAN; HUMAN CELL; METABOLOMICS; OVARY CANCER; PURINE METABOLISM; PYRIMIDINE METABOLISM; ANTAGONISTS AND INHIBITORS; CITRIC ACID CYCLE; CLUSTER ANALYSIS; LIPID METABOLISM; MASS SPECTROMETRY; METABOLISM; METABOLOME; NEOPLASM; PENTOSE PHOSPHATE CYCLE; PROCEDURES; TUMOR CELL LINE;

AMINO ACIDS; CELL LINE, TUMOR; CITRIC ACID CYCLE; CLUSTER ANALYSIS; CREATINE; GLYCOLYSIS; HUMANS; LIPID METABOLISM; MASS SPECTROMETRY; METABOLIC NETWORKS AND PATHWAYS; METABOLOME; METABOLOMICS; NEOPLASMS; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; PENTOSE PHOSPHATE PATHWAY; PURINES; PYRIMIDINES;

EID: 84915804111     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0114019     Document Type: Article

References (48)

1. Tan B, Young DA, Lu ZH, Wang T, Meier TI, et al. (2013) Pharmacological inhibition of nicotinamide phosphoribosyltransferase (NAMPT), an enzyme essential for NAD biosynthesis, in human cancer cells: metabolic basis and potential clinical implications. J Biol Chem 288: 3500-3511.
2. Garten A, Petzold S, Körner A, Imai S-i, Kiess W (2009) NAMPTNAMPTNAMPT: Linking NAD biology, metabolism, and cancer. Trends Endocrinol Metab 20: 130-138.
3. Kirkland JB (2009) Niacin status, NAD distribution and ADP-ribose metabolism. Curr Pharm Des 15: 3-11.
4. Magni G, Amici A, Emanuelli M, Orsomando G, Raffaelli N, et al. (2004) Enzymology of NAD+ homeostasis in man. Cell Mol Life Sci 61: 19-34.
5. Sauve AA (2008) NAD+ and vitamin B3: from metabolism to therapies. J Pharmacol Exp Ther 324: 883-893.
6. Olesen UH, Thougaard AV, Jensen PB, Sehested M (2010) A preclinical study on the rescue of normal tissue by nicotinic acid in high dose treatment with APO866, a specific nicotinamide phosphoribosyltransferase inhibitor. Mol Cancer Ther 9: 1609-1617.
7. Olesen UH, Christensen MK, Björkling F, Jäättelä M, Jensen PB, et al. (2008) Anticancer agent CHS-828 inhibits cellular synthesis of NAD. Biochem Biophys Res Commun 367: 799-804.
8. Watson M, Roulston A, Bélec L, Billot X, et al. (2009) The small molecule GMX1778 is a potent inhibitor of NAD+ biosynthesis: strategy for enhanced therapy in nicotinic acid phosphoribosyltransferase 1-deficient tumors. Mol Cell Biol 29: 5872-5888.
9. Samal B, Sun Y, Stearns G, Xie C, Suggs S, McNiece I (1994) Cloning and characterization of the cDNA encoding a novel human pre-B-cell colony enhancing factor. Mol Cell Biol 14: 1431-1437.
10. Revollo JR, Grimm AA, Imai S (2004) The NAD biosynthesis pathway mediated by nicotinamide phosphoribosyltransferase regulates Sir2 activity in mammalian cells. J Biol Chem 279: 50754-50763.
11. Rongvaux A, Galli M, Denanglaire S, Van Gool F, Drèze PL, et al. (2008) Nicotinamide phosphoribosyl transferase/pre-B cell colony-enhancing factor/visfatin is required for lymphocyte development and cellular resistance to genotoxic stress. J Immunol 181: 4685-4695.
12. Imai S (2009) Nicotinamide phosphoribosyltransferase (NAMPT). A link between NAD biology, metabolism, and diseases. Curr Pharm Des 15: 20-28.
13. Khan JA, Forouhar F, Tao X, Tong L (2007) Nicotinamide adenine dinucleotide metabolism as an attractive target for drug discovery. Expert Opin Ther Targets 11: 695-705.
14. Luk T, Malam Z, Marshall JC. (2008) Pre-B cell colony-enhancing factor (PBEF)/visfatin: a novel mediator of innate immunity. J Leukoc Biol 83: 804-816
15. Bi TQ, Che XM, Liao XH., Zhang DJ, Long HL, et al. (2011) Overexpression of NAMPT in gastric cancer and chemopotentiating effects of the NAMPT inhibitor FK866 in combination with fluorouracil. Oncol Rep 26: 1251-1257.
16. Hufton SE, Moerkerk PT, Brandwijk R, de Bruïne AP, Arends JW, et al. (1999) A profile of differentially expressed genes in primary colorectal cancer using suppression subtractive hybridization. FEBS Lett 463: 77-82.
17. Van Beijnum JR, Moerkerk PT, Gerbers AJ, De Bruïne AP, Arends JW, et al. (2002) Target validation for genomics using peptide-specific phage antibodies: a study of five gene products overexpressed in colorectal cancer. Int J Cancer 101: 118-127.
18. Wang B, Hasan MK, Alvarado E, Yuan H, Wu H, et al. (2011) NAMPT overexpression in prostate cancer and its contribution to tumor cell survival and stress response. Oncogene 30: 907-921.
19. Nakajima TE, Yamada Y, Hamano T, Furuta K, Gotoda T, et al. (2009) Adipocytokine levels in gastric cancer patients: resistin and visfatin as biomarkers of gastric cancer. J Gastroenterol 44: 685-690.
20. Busso N, Karababa M, Nobile M, Rolaz A, Van Gool F, et al. (2008) Pharmacological inhibition of nicotinamide phosphoribosyltransferase/visfatin enzymatic activity identifies a new inflammatory pathway linked to NAD. PLoS One 3: e2267.
21. Hasmann M, Schemainda I (2003) FK866, a highly specific noncompetitive inhibitor of nicotinamide phosphoribosyltransferase, represents a novel mechanism for induction of tumor cell apoptosis. Cancer Res 63: 7436-7442.
22. Yang H, Yang T, Baur JA, Perez E, Carmona JJ, et al. (2007) Nutrient-sensitive mitochondrial NAD+ levels dictate cell survival. Cell 130: 1095-1107.
23. Drevs J, Löser R, Rattel B, Esser N (2003) Antiangiogenic potency of FK866/K22.175, a new inhibitor of intracellular NAD biosynthesis, in murine renal cell carcinoma. Anticancer Res 23: 4853-4858.
24. Muruganandham M, Alfieri AA, Matei C, Chen Y, Sukenick G, et al. (2005) Metabolic signatures associated with a NAD synthesis inhibitor-induced tumor apoptosis identified by 1H-decoupled 31P magnetic resonance spectroscopy. Clin Cancer Res 11: 3503-3513.
25. Du L, Zhang X, Han YY, Burke NA, Kochanek PM, et al. (2003) Intramitochondrial poly(ADP-ribosylation) contributes to NAD depletion and cell death induced by oxidative stress. J Biol Chem 278: 18426-18433.
26. Pillai JB, Isbatan A, Imai S, Gupta MP (2005) Poly(ADP-ribose) polymerase-1-dependent cardiac myocyte cell death during heart failure is mediated by NAD depletion and reduced Sir2 deacetylase activity. J Biol Chem 280: 43121-43130.
27. Yu SW, Wang H, Poitras MF, Coombs C, Bowers WJ, et al. (2002) Mediation of poly(ADP-ribose) polymerase-1-dependent cell death by apoptosis-inducing factor. Science 297: 259-263.
28. Luo J, Nikolaev AY, Imai S, Chen D, Su F, et al. (2001) Negative control of p53 by Sir2 promotes cell survival under stress. Cell 107: 137-148.
29. Saunders LR, Verdin E. (2007) Sirtuins: critical regulators at the crossroads between cancer and aging. Oncogene 26: 5489-5504.
30. Van Gool F, Gallí M, Gueydan C, Kruys V, Prevot PP, et al. (2009) Intracellular NAD levels regulate tumor necrosis factor protein synthesis in a sirtuin dependent manner. Nat Med 15: 206-210.
31. Pittelli M, Formentini L, Faraco G, Lapucci A, Rapizzi E, et al. (2010) Inhibition of nicotinamide phosphoribosyltransferase: cellular bioenergetics reveals a mitochondrial insensitive NAD pool. J Biol Chem 285: 34106-34114.
32. Khan JA, Tao X, Tong L (2006) Molecular basis for the inhibition of human NMPRTase, a novel target for anticancer agents. Nat Struct Mol Biol 13: 582-588.
33. Nahimana A, Attinger A, Aubry D, Greaney P, Ireson C, et al. (2009) The NAD biosynthesis inhibitor APO866 has potent antitumor activity against hematologic malignancies. Blood 113: 3276-3286.
34. Holen K, Saltz LB, Hollywood E, Burk K, Hanauske AR (2008) The pharmacokinetics, toxicities, and biologic effects of FK866, a nicotinamide adenine dinucleotide biosynthesis inhibitor. Invest New Drugs 26: 45-51.
35. Galli U, Travelli C, Massarotti A, Fakhfouri G, et al. (2013) Medicinal chemistry of nicotinamide phosphoribosyltransferase (NAMPT) inhibitors. J Med Chem 56: 6279-6296.
36. Galli U, Ercolano E, Carraro L, Blasi Roman CR, Sorba G, et al. (2008) Synthesis and biological evaluation of isosteric analogues of FK866, an inhibitor of NAD salvage. Chem Med Chem 3: 771-779.
37. Tong L, Tao X, Khan JA (2008, January 24) U. S. Patent 0020413.
38. Zou W, Tolstikov V (2009). Pattern recognition and pathway analysis with genetic algorithms in mass spectrometry based metabolomics. Algorithms 2: 638-666.
39. Urayama S, Zou W, Brooks K, Tolstikov V (2010). Comprehensive mass spectrometry based metabolic profiling of blood plasma reveals potent discriminatory classifiers of pancreatic cancer. Rapid Commun Mass Spectrom 24: 613-620.
40. Tolstikov V, Nikolayev A, Laska AD, Kuo M-S, Duffin KL (2013, June 9-13) Metabolomics input in a search for chronic kidney disease targets utilizing clinical cross-platform omics data integration. Paper presented at: ASMS, Minneapolis, MN.
41. Chan ECY, Pasikanti KK, Nicholson JK (2011) Global urinary metabolic profiling procedures using gas chromatography-mass spectrometry. Nature Protocols 6: 1483-1499.
42. Dunn WB, Broadhurst D, Begley P, Zelena E, Francis-McIntyre S, et al. (2011) Procedures for large-scale metabolic profiling of serum and plasma using gas chromatography and liquid chromatography coupled to mass spectrometry. Nature Protocols 6: 1060-1083.
43. Yuan M, Breitkopf SB, Yang X, Asara JM (2012) A positive/negative ion-switching, targeted mass spectrometry-based metabolomics platform for bodily fluids, cells, and fresh and fixed tissue. Nature Protocols 7: 872-881.
44. Want EJ, Wilson ID, Gika H, Theodoridis G, Plumb RS, Shockcor J, Holmes E, Nicholson JK (2010) Global metabolic profiling procedures for urine using UPLC-MS. Nature Protocols 5: 1005-1018.
45. Xia J, Mandal R, Sinelnikov IV, Broadhurst D, Wishart DS (2012) MetaboAnalyst 2.0 - a comprehensive server for metabolomic data analysis. Nucl Acids Res 40: W127-W133.
46. Xiao Y, Elkins K, Durieux JK, Lee L, Oeh J, et al. (2013) Dependence of tumor cell lines and patient-derived tumors on the NAD salvage pathway renders them sensitive to NAMPT inhibition with GNE-618. Neoplasia 15: 1151-1160.
47. Du J, Cleghorn WM, Contreras L, Lindasy K, Rountree AM, et al. (2013). Inhibition of mitochondrial pyruvate transport by zaprinast causes massive accumulation of aspartate at the expense of glutamate in the retina. J Biol Chem 288: 36129-36140.
48. Bowlby SC, Thomas MJ, D'Agostino RB Jr, Kridel SJ (2012) Nicotinamide phosphoribosyl transferase (NAMPT) is required for de novo lipogenesis in tumor cells. PLoS One 7: e40195.